<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034498</url>
  </required_header>
  <id_info>
    <org_study_id>Occ2018-01</org_study_id>
    <nct_id>NCT04034498</nct_id>
  </id_info>
  <brief_title>A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® PmVSD Occluder in Patients With Perimembranous Ventricular Septal Defects</brief_title>
  <official_title>A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® Perimembranous Ventricular Septal Defect (PmVSD) Occluder in Patients With Perimembranous Ventricular Septal Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this registry is to gain more insight on the clinical use of the Occlutech
      perimembranous VSD occluder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2019</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>To confirm the efficacy of Occlutech PmVSD in patients requiring transcatheter occlusion (closure) of perimembranous ventricular septal defects.</measure>
    <time_frame>1 year following implantation</time_frame>
    <description>The primary efficacy endpoint is defined as successful implantation of the device with a proper closure of the pmVSD (defined as reduction in VSD shunt of more than one grade as assessed by TTE post implantation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To confirm the safety of Occlutech PmVSD in patients requiring transcatheter occlusion (closure) of perimembranous ventricular septal defects.</measure>
    <time_frame>1 year following implantation</time_frame>
    <description>The primary safety endpoint is defined as absence of Serious Adverse Device Effects (SADEs) including procedure-related death, procedure-related stroke, systemic embolism, severe hemolysis, complete heart block requiring pacemaker implantation or device explantation, new-onset of severe tricuspid regurgitation (TR), new onset of severe aortic regurgitation (AR), device embolization, severe right-left ventricular outflow obstruction (RVOTO-LVOTO), cardiac tamponade, infective endocarditis or vascular complications requiring surgery.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Perimembranous Ventricular Septal Defect</condition>
  <eligibility>
    <study_pop>
      <textblock>
        There will be no pre-selection of patients for enrollment in this registry. The criteria
        provided in the Instructions For Use should be followed. The study cohort will thus consist
        of consecutively enrolled patients at the discretion of the treating physician
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with haemodynamically significant perimembranous defects which are located in the
        ventricular septum

        Exclusion Criteria:

        Occlutech® PmVSD Occluder is contraindicated for the following:

          -  Patients with defects less than 2 mm aortic rim and/or interference with the aortic or
             atrioventricular valves

          -  Patients less than 10.0 kg

          -  Patients with sepsis (local or generalized)

          -  Patients with left ventricle to right atrial shunting

          -  Patients with right to left shunting through the defect

          -  Patients with PmVSD with an aneurysm and multiple shunts that could not be
             successfully closed with one device

          -  Patients with complex heart lesions such as tetralogy of fallot

          -  History of repeated pulmonary infection

          -  Any type of serious infection 1 month prior to procedure

          -  Malignancy where life expectancy is less than 3 years

          -  Demonstrated intracardiac thrombi on echocardiography

          -  Patients with allergy to anti-platelet or anticoagulant therapy

          -  Patients with allergy to nickel and/or titanium and/or nickel/titanium based materials

          -  Patients with intolerance to contrast agents

          -  Patients with active bacterial infections

          -  Patients with very small vessels which are not suitable for recommended delivery
             sheath sizes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gönül Sönmez Utkan</last_name>
    <phone>+90 212465 0497</phone>
    <email>clinicaltrials@occlutech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens' Hospital of Colorado &amp; University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gareth J Morgan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ludwig Maximilians University</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Dalla Pozza, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Asaad Khoury, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Worakan Promphan, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Songkla University</name>
      <address>
        <city>Hat Yai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Supapron Roymanee, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital 1</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Do Nguyen Tin, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Children Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tran Cong Bao Phung, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Yen, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center HCMC</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dao Anh Quoc, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Thailand</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

